PLX038

DRUG5 trials

Sponsors

Institut Curie, Institut Curie, ProLynx LLC, National Cancer Institute (NCI), Institut Curie

Conditions

Advanced or metastatic triple-negative breast cancerBreastCancerEpendymomaExtra-Pulmonary Small Cell CarcinomasGlioblastomaGliomaMedulloblastoma

Phase 1

A Phase I Study of PLX038 in Patients With Advanced Solid Tumors

CompletedNCT02646852

ProLynx LLCCancer, Neoplasms, Tumors

Start: 2016-03-31End: 2023-07-31Updated: 2023-07-12

PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers

CompletedNCT04209595

National Cancer Institute (NCI)Extra-Pulmonary Small Cell Carcinomas, Small Cell Lung Cancer

Start: 2020-04-08End: 2025-02-24Updated: 2026-08-26

PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications

RecruitingNCT06161519

National Cancer Institute (NCI)Ependymoma, Glioblastoma, Glioma +1

Start: 2024-01-31End: 2033-11-14Target: 146Updated: 2026-08-12

Phase 2

"TOPOLOGY" : A phase II study to evaluate the efficacy and toxicities of PLX038, in patients with locally advanced or metastatic triple-negative breast cancer

CompletedCTIS2022-501507-27-00

Institut Curie, Institut CurieAdvanced or metastatic triple-negative breast cancer

Start: 2024-04-17End: 2025-05-15Target: 44Updated: 2025-12-17

A Study to Evaluate the Efficacy and Toxicities of PLX038, in Patients With Locally Advanced or Metastatic Triple-negative Breast Cancer

TerminatedNCT06162351

Institut CurieBreast, Cancer

Start: 2024-04-17End: 2025-05-15Updated: 2026-01-02

Related Papers

TOPOLOGY: A phase II study to evaluate the efficacy and toxicities of PLX038, in patients with locally advanced or metastatic triple-negative breast cancer.

Journal of Clinical Oncology2024-06-011 citations